Routine Laboratory Results and Thirty Day and One-Year Mortality Risk Following Hospitalization with Acute Decompensated Heart Failure

Victor Novack1,2, Michael Pencina2, Doron Zahger3, Lior Fuchs1, Roman Nevzorov1, Allan Jotkowitz1, Avi Porath1

1 Clinical Research Center, Soroka University Medical Center, Beer-Sheva, Israel, 2 Harvard Clinical Research Institute, Boston, Massachusetts, United States of America, 3 Cardiology, Soroka University Medical Center, Beer-Sheva, Israel

Introduction

Heart failure (HF) is a major worldwide public health concern. Currently, more than 5 million people in the United States are diagnosed with HF, and approximately 550,000 new cases are reported annually with an estimated annual cost of $33.2 billion.[1]

Several blood tests are performed uniformly in patients hospitalized with acute decompensated heart failure; a complete blood count, electrolytes, renal function, glucose, albumin and uric acid. Anemia is a powerful independent predictor of death and recurrent hospitalization in different subclasses of HF.[2] Single measurement of the total white blood cells (WBC) count is associated with all-cause and cardiovascular mortality in clinically stable patients with left ventricular (LV) systolic dysfunction.[3,4] Renal impairment is a frequent prognosticator for mortality in patients hospitalized with HF.[3,6] Hyponatremia and hyperkalemia are common in patients admitted with heart failure and have been shown to predict mortality.[7,8,9,10] Uric acid (UA) levels can be a marker of impaired prognosis in hospitalized patients with acute HF and LV systolic dysfunction.[11,12] Low albumin concentration can be an indicator of inflammation superimposed on cardiac cachexia – both factors associated with increased mortality in populations with HF.[13,14] Finally, high blood glucose levels are associated with worsening of HF in diabetic and non-diabetic subjects.[15,16]

Lately numerous new biomarkers were evaluated as prognosticators in HF population.[17,18,19] However, the limited availability of these tests and lack of the standardization makes their use problematic in day-to-day clinical practice. We hypothesize that routine laboratory tests can be used for the same purpose, i.e. prediction of outcome in patients hospitalized with acute HF.

The purpose of this study was to construct and validate a predictive tool for 30-day and one-year all cause mortality based on a minimal set of admission routine laboratory tests together.
with basic patient data in a nationally representative group of patients hospitalized for acute heart failure.

**Methods**

**Ethics Statement**

The study was a part of a quality control project. For the purposes of the analysis deidentified database was created from the hospitals administrative databases. Therefore no Ethics Committee approval or subject informed consent was needed.

All heart failure admissions to the seven major general hospitals of the Clalit Health Services throughout Israel (30% of general hospitals beds in the country) from November 2001 to June 2005 were screened. Each of the seven general hospitals transfers patient level data to a central data warehouse, which is connected to the computerized database of the Interior Ministry. The latter provides real life information on the vital status of citizens. Patients are identified in all databases by the unique national ID number. The medical records of patients with primary discharge diagnosis consistent with HF (International Classification of Diseases, Ninth Revision code 428) and no concurrent myocardial infarction were assessed electronically. For a sub-cohort of Clalit insured patients (approximately 80% of the cohort), data on pre-hospitalization medications were obtained.

We assessed the first available results of the laboratory test performed within first 24 hours of admission. Based on predefined definitions based on limits of normal range and the assessment of the relationships between laboratory values and one-year mortality we dichotomized the following variables: sodium (hyponatremia <136 meq/L), urea (elevated ≥43 mg/dL), anemia (hematocrit <40% in men and <36% in women), albumin (low <3.5 g/dL), uric acid (elevated >6.5 mg/dL) and glucose (elevated≥200 mg/dL) and trichotomized white blood cells count (WBC leukocytosis >10.8 10^3/mm^3, leukopenia<4.3 10^3/mm^3) and potassium (hyperkalemia>5.0 meq/L, hypokalemia<3.5 meq/L). Glomerular filtration rate (GFR) was estimated based on the Modification of Diet in Renal Disease (MDRD) Study equation and dichotomized into two groups: ≥60 ml/min and <60 ml/min. We used the Charlson index to compute the burden of comorbid conditions.[20]

**Statistical Analysis**

The primary outcomes were 30-day and 1 year all cause deaths. For univariate analysis, we used t-test for comparison of continuous variables, and Pearson’s chi-square test for categorical variables. Mann-Whitney test was used for comparison of variables with non-normal distribution.

Risk prediction models were developed for 30-day and one-year mortality. Since full follow-up was available on all participants and primary interest was on event occurrence rather than its timing, logistic regression was employed. Variable selection in multivariable modeling was based on clinical and statistical significance and performed in a hierarchical fashion, following the approach outlined in.[21] In case of pair-wise correlations between laboratory tests exceeding 0.50, we chose only one of those tests: the one with stronger individual effect size (this led to selecting urea over GFR and RBC over hematocrit).

First, all laboratory tests results significantly associated with one-year mortality in univariate analysis were included into the regression models for 30-day and one-year death as continuous variables. Since WBC and potassium levels had non-linear relationship with one-year mortality, those variables were included in a categorical form (three groups); below low limit of normal, normal (reference group) and above upper limit of normal. Multiple partial tests were performed to confirm their significance as a group. At the next step baseline clinical and demographic characteristics: age, sex, history of myocardial infarction, dyslipidemia, arterial hypertension, diabetes, history of bypass surgery, atrial fibrillation, chronic obstructive pulmonary disease, dementia and Charlson index were added. Finally pre-hospitalization medications were introduced: angiotensin-converting enzyme inhibitors, angiotensin receptors blockers, β-blockers, statins, spironolactone, digoxin and diuretics and tests of significance for laboratory variables were repeated.

To investigate the most appropriate functional form (linear, quadratic etc.) of the relationship between laboratory tests and one-year mortality we fit generalized additive models which allow for modeling the predictors as spline functions thus relaxing the assumption of linearity (SAS proc GAM).[22] The results confirmed those obtained by crudely plotting event rates across sub-categories of laboratory tests.

Discriminatory abilities of the models were assessed by area under the receiver operating characteristics (ROC) curves (AUC) for death probability calculated for each subject. Discriminatory abilities of the models were compared using a test for difference of two AUCs proposed by DeLong et al. and available through the roccontrast option in SAS proc logistic. [23] Calibration of the models was evaluated by Hosmer and Lemeshow chi-square test of goodness of fit. For model derivation we randomly selected 3 out of 7 hospitals. Once the models were derived and shown to be valid in the other 4 hospitals, the two cohorts (derivation and validation) were combined for further analysis.

To further evaluate the models’ performance the echocardiography data obtained within ±3 month from the index hospitalization for 854 subjects admitted to one of the hospital were assessed. Ejection fraction and presence of diastolic dysfunction were included into the models predicting 30-day and 1 year mortality and c-statistics were calculated.

To simplify clinical application the model was repeated with significant laboratory test results dichotomized or trichotomized as described earlier and three of those variables with the highest odds ratios for one-year mortality were selected for inclusion into the clinical score. We assigned 1 points for each pathological result. Combined score was calculated for each patient. Kaplan-Meier analysis with log-rank test was used for assessing the relationship between the combined score and one-year mortality. All reported P values are two-sided and p<0.05 was considered significant.

**Results**

**Study population**

During 44 months of the study 15,661 admissions to seven hospitals with a principal diagnosis of heart failure decompensation were recorded 45.2% of which were repeat admissions. Overall 8,246 patients with a first HF admission during the study period comprised the study cohort. Median hospitalization duration was 4 days (interquartile range [IQR] of 2 to 7 days). During the hospital stay 467 patients (5.7%) died. Thirty day mortality rate was 8.5% (701 patients) and one-year mortality rate was 28.7% (2,356 patients).

Table 1 depicts baseline characteristics of the patient population stratified by one-year mortality. The deceased patients compared with the one year survivors were older (79.4%±10.9% vs. 74.0%±11.8%; p<0.001), and had more comorbidities as indicated by higher Charlson Comorbidity index (5.3%±1.8% vs. 4.3%±1.7%;p<0.001). Although the deceased patients had lower prevalence of diabetes mellitus (35.3% vs. 39.5%; p<0.001), hypertension (53.6% vs. 61.2%; p<0.001), dyslipidemia (18.6% vs.
29.1%; p < 0.001) and previous CABG surgery (13.8% vs. 17.6%), they had higher prevalence of atrial fibrillation (40.3% vs. 34.2%), valvular diseases (15.0% vs. 11.1%), acute and chronic renal failure (8.2% vs. 3.3% and 21.4% vs. 11.8% respectively), anemia (27.6% vs. 22.0%), pleural effusion or ascites (10.3% vs. 7.0%), chronic obstructive pulmonary disease (16.8% vs. 13.2%) and much higher prevalence of dementia (9.4% vs. 2.9%, all with p-value < 0.001). Of note, survivors had higher rates of life saving cardiac medications use, such as ACE inhibitors (10.1% vs. 7.1%), β-blockers (59.1% vs. 50.0%), statins (42.7% vs. 29.8%) and aspirin (54.1% vs. 48.7%) but lower rates of spironolacton (18.4% vs. 23.4%) and diuretics use (73.9% vs. 78.8%, all with p-value < 0.001). All laboratory values at admission (except glucose levels) were significantly different between survivors and deceased.

**Laboratory analysis (Table 2)**

During the first 24 hours of admission sodium levels were available for 7,963 patients (96.6%, Figure 1, Figure 2). Hyponatremia was found in 1755 patients (22.0%) and 1,428 (14.8%) had hyperkalemia. One-year crude relative risk (RR) of death in patients with hyponatremia at admission was 1.54 (95%CI 1.43–1.66) and 1.40 (95%CI 1.29–1.52) for hyperkalemia. Hematocrit results were available in 8,047 patients (97.6%). Anemia was found in 57.1% of the patients and was more frequent among males: 63.7% vs. 49.9% in female patients, p < 0.001. Patients with anemia had a one-year mortality RR = 1.24 (95%CI 1.17–1.34) as compared to non-anemic group. White blood count was available in 8,064 cases (97.8%). Leukocytosis was found in 26.8% of the patients and was associated with one-year death: RR = 1.29 (95%CI 1.20–1.38). Serum creatinine results were available for 8,038 patients (97.5%). GFR less than 60 ml/min was found in 84.2%, while 25.2% of the patients had GFR < 30 ml/min. Patients with GFR < 30 ml/min had higher one-year mortality risk: RR = 1.62 (95%CI 1.51–1.73). Blood urea results were available in 8,034 cases (97.5%).

**Table 1. Baseline characteristics of the patient population.**

| Co-morbidities | All patients | One-year survivors | Deceased | p-value |
|----------------|--------------|-------------------|----------|---------|
| Age, year      | N = 8,246    | N = 5,881         | N = 2,365|         |
| Gender, female (%) | 47.8        | 47.1              | 49.6     | 0.04    |
| Charlson score, (points) | 4.6±1.8    | 4.3±1.7           | 5.3±1.8  | <0.001  |
| Ischemic heart disease, (%) | 60.8        | 61.4              | 59.4     | 0.10    |
| Previous myocardial infarction, (%) | 24.2        | 24.2              | 24.4     | 0.84    |
| Diabetes, (%) | 38.3         | 39.5              | 35.3     | <0.001  |
| Arterial hypertension, (%) | 59.0        | 61.2              | 53.6     | <0.001  |
| Dyslipidemia, (%) | 26.1        | 29.1              | 18.6     | <0.001  |
| Atrial fibrillation, (%) | 35.9        | 34.2              | 40.3     | <0.001  |
| Non ischemic cardiomyopathy, (%) | 4.1         | 4.2               | 3.7      | 0.25    |
| Previous CABG, (%) | 16.5        | 17.6              | 13.8     | <0.001  |
| Previous valvular surgery, (%) | 3.3         | 3.4               | 3.1      | 0.49    |
| Any valvular disease, (%) | 27.7        | 27.5              | 28.2     | 0.47    |
| Aortic valve disease, (%) | 12.2        | 11.1              | 15.0     | <0.001  |
| Mitral valve disease, (%) | 18.5        | 19.1              | 17.1     | 0.03    |
| Chronic renal failure, (%) | 14.5        | 11.8              | 21.4     | <0.001  |
| Acute renal failure, (%) | 4.8         | 3.3               | 8.2      | <0.001  |
| Anemia, (%) | 23.6         | 22.0              | 27.6     | <0.001  |
| Pleural effusion or ascites, (%) | 7.9         | 7.0               | 10.3     | <0.001  |
| Chronic obstructive pulmonary disease, (%) | 14.2       | 13.2              | 16.8     | <0.001  |
| Dementia, (%) | 4.7          | 2.9               | 9.4      | <0.001  |
| Medications at 3 months prior to hospitalization (n = 7,105) | | | | |
| Angiotensin-converting enzyme inhibitors, (%) | 59.9        | 60.6              | 58.0     | 0.04    |
| Angiotensin receptor blockers, (%) | 9.3         | 10.1              | 7.1      | <0.001  |
| Aspirin, (%) | 52.5         | 54.1              | 48.7     | <0.001  |
| β-blockers, (%) | 56.5        | 59.1              | 50.0     | <0.001  |
| Statins, (%) | 39.0         | 42.7              | 29.8     | <0.001  |
| Spironolactone, (%) | 19.8        | 18.4              | 23.4     | <0.001  |
| Digoxin, (%) | 15.1         | 14.6              | 16.4     | 0.05    |
| Diuretics, (%) | 75.3         | 73.9              | 78.8     | <0.001  |

doi:10.1371/journal.pone.0012184.t001
(97.4%) patients. High levels were present in 5,648 (70.3%) and were associated with one-year mortality: RR = 2.26 (95%CI 1.90–2.26).

Hypoalbuminemia was found in 36.3% out of 7,775 tested patients and was associated with one-year mortality: RR = 1.85 (95%CI 1.72–1.98). Uric acid levels were available in 6,755 patients (81.9%). An elevated level of uric acid was associated with one-year mortality: RR = 1.42 (95%CI 1.30–1.56).

Glucose results were available for 8,028 patients (97.4%) and 1,897 (23.6%) had levels above 200 mg/dL. There was no association between glucose.

Table 2. Baseline laboratory characteristics of the patient population.

|                         | All patients | One-year survivors | Deceased   | p-value |
|-------------------------|--------------|-------------------|------------|---------|
| **Laboratory values at admission** |              |                   |            |         |
| Hematocrit, % (n = 8,047) | 37.1±5.7     | 37.5±5.7          | 36.2±5.8   | <0.001  |
| RBC, 10^3/mm³ (n = 8,065) | 4.29±0.71    | 4.35±0.69         | 4.15±0.73  | <0.001  |
| WBC, 10^3/mm³ (n = 8,064) | 9.8±4.6      | 9.5±4.1           | 10.3±5.5   | <0.001  |
| Blood urea, (n = 8,034)   | 62.7±37.4    | 56.5±31.6         | 78.0±45.5  | <0.001  |
| Glomerular filtration rate, ml/min (n = 7,685) | 42.3±19.0  | 44.6±18.6         | 36.8±18.6  | <0.001  |
| Sodium, mEq/L (n = 7,963) | 137.3±4.8    | 137.6±4.5         | 136.4±5.3  | <0.001  |
| Potassium, mEq/L (n = 7,601) | 4.5±0.7      | 4.5±0.6           | 4.6±0.8    | <0.001  |
| Albumin, g/dL (n = 7,775) | 3.6±0.5      | 3.7±0.5           | 3.4±0.5    | <0.001  |
| Glucose, mg/dL (n = 8,028) | 162.7±80.6   | 162.2±79.4        | 164.0±83.3 | 0.38    |
| Uric acid, mg/dL (n = 6,755) | 8.0±2.6      | 7.7±2.3           | 8.8±3.0    | <0.001  |

doi:10.1371/journal.pone.0012184.t002

Figure 1. Results of the laboratory tests and one year mortality rates. Three laboratory tests with abnormal results associated with one-year mortality and highest odds ratio (albumin, sodium and urea).
doi:10.1371/journal.pone.0012184.g001
patients with diabetes (73.9% had glucose \(\geq 200\) mg/dL), nor without (27.3% had glucose > 200 mg/dL): \(p = 0.49\) and \(p = 0.17\) respectively.

Multivariable Analysis

Five laboratory test results: albumin, sodium, blood urea, uric acid and WBC were significantly related to 30-day and one-year mortality, as a group and individually, in unadjusted models as well as in models that adjusted for baseline clinical and demographic characteristics and for baseline medications. Corresponding odds ratios per one standard deviation increase are presented in Table 3. Generalized additive models revealed no meaningful departures from linearity for the laboratory variables. Hence, no new cut-points

Table 3. Odds ratios* for five laboratory values calculated per standard deviation for sodium, blood urea, albumin and uric acid and for leucopenia and leukocytosis for WBC.

|                        | One-year mortality |            |            | 30-day mortality |            |            |
|------------------------|--------------------|------------|------------|------------------|------------|------------|
|                        | Odds ratio         | 95% CI     | Odds ratio | 95% CI           |            |            |
| Sodium                 | 0.80               | 0.75-0.85  | 0.84       | 0.77-0.92        |            |            |
| Blood urea             | 1.42               | 1.32-1.52  | 1.46       | 1.33-1.59        |            |            |
| Albumin                | 0.64               | 0.60-0.69  | 0.63       | 0.57-0.69        |            |            |
| WBC, normal range      | Referent = 1.00    |            |            |                  |            |            |
| WBC < 4,300 \(10^9\)/\(mm^3\) | 1.33             | 0.91-1.96  | 1.19       | 0.63-2.24        |            |            |
| WBC > 10,800 \(10^9\)/\(mm^3\) | 1.23            | 1.08-1.41  | 1.60       | 1.31-1.96        |            |            |
| Uric acid              | 1.31               | 1.23-1.40  | 1.31       | 1.19-1.44        |            |            |

*odds ratios expressed per one standard deviation increase in laboratory test level except for WBC which compares abnormal values to a reference group. Derived from 30-day and one-year mortality prediction logistic regression models inclusive of laboratory tests, demographics and comorbidities.

doi:10.1371/journal.pone.0012184.t003

Figure 2. Results of the laboratory tests and one year mortality rates. Three laboratory tests with abnormal results associated with one-year mortality and lowest odds ratio (uric acid, potassium and leukocytosis). doi:10.1371/journal.pone.0012184.g002
emerged. Figure 3 and Figure 4 present odds ratios for laboratory values dichotomized using standard cut-points.

Discriminative and calibration abilities of the models for 30-day and one-year mortality prediction

C-statistics in the derivation cohort (3 hospitals, 3,941 subjects) and the validation cohort (4 hospitals, 4,305 subjects) were similar for all models and hence we decided to pool them and present results on combined data for increased precision. Table 4 presents the discriminative characteristics and calibration results for different combinations of variable groups (demographics, comorbidities, laboratory results and pre-hospitalization medications). Addition of the 5 laboratory test results to a model with baseline clinical and demographic characteristics increased the c statistic from 0.72 to 0.81 for 30-day mortality model and from 0.69 to 0.76 for one-year mortality model with both increases highly statistically significant (both p-values <0.0001). Figure 5 presents the calibration plot for the full model for 30-day and 1 year mortality prediction.

Using the maximum sum of sensitivity and specificity as a rule to obtain the best cut-off point for classification we arrived at the following results:

For 1 year mortality the classification threshold was 0.28 with a sensitivity of 68.8% and specificity of 72.7%. Observed mortality rate for subjects classified as high risk was 48.2% (predicted mortality 47.7%) and as low risk 14.8% (predicted mortality 15.2%).

![Figure 3. Odds ratios of laboratory values for 30-day all cause mortality. Five categorized laboratory tests found to be significant in the multivariable analysis as continuous variables are presented. doi:10.1371/journal.pone.0012184.g003](image-url)
For 30-day mortality the classification threshold was 0.08 with a sensitivity of 73.1% and specificity of 70.1%. Observed mortality rate for subjects classified as high risk was 19.5% (predicted mortality 18.8%) and as low risk 3.0% (predicted mortality 3.3%).

Echocardiography results
We included echocardiography data obtained within 6 months from the index hospitalization for 854 subjects admitted to one of the hospitals. Severe systolic dysfunction (ejection fraction <30%) was found in 41.2% and diastolic dysfunction was diagnosed in 35.3% of the patients. Ejection fraction and diastolic dysfunction were added to demographic characteristics and comorbidities variables group. Inclusion of echocardiography results did not change the overall discriminative ability of the models or calibration: neither for 30-day, nor for one-year mortality prediction.

Simplified clinical score
A simplified version of the clinical prediction score based on three dichotomized abnormal laboratory results (blood albumin, sodium and urea, available for 7,608 patients, 92.3%) was developed. One-year logistic regression model inclusive of uremia,
Assessing the prognosis of HF patients at admission is essential for several reasons. It can help determine the intensity of initial treatment and monitoring, facilitate triage decisions, provide initial information to patients and relatives, and is also important for audit and retrospective quality control.

We found that the addition of readily available laboratory tests improve significantly the predictive ability of the survival models based on clinical and demographic characteristics. A few routine test results (albumin, urea, WBC, uric acid and sodium) have a discriminative ability for 30-day and one-year mortality predictions comparable with more sophisticated and expensive biomarkers such as BNP, NT-proBNP, H-FABP, Mid-Regional pro-Adrenomedullin (MR-proADM) and PTX3.[17,18,19]

Several scores were proposed for predicting survival in these patients, but they vary in the choice, extent and availability of the required components. Lee et al [24] developed a score composed of eleven variables, including demographic characteristics, comorbid conditions, clinical signs and selected laboratory values obtained within twenty four hours of admission. The overall prediction accuracy for this score is similar to the discriminative power of our full models (demographic characteristics, comorbidities and laboratory tests results): c-statistics for 30-days 0.79 vs. 0.81 and for one-year mortality 0.76 vs. 0.76 respectively. However, it requires data on vital signs such as blood pressure and respiratory rates. The Heart Failure Survival Score [HFSS] requires more elaborate calculation and stratifies patients with NYHA class III and IV based on history, heart rate, LVEF, BP, IVCD, sodium and peak VO₂.[25] More recently, The Seattle Heart Failure Model was developed which uses a combination of history, ejection fraction, BP, medication use and laboratory values to predict survival for ambulatory and hospitalized patients with HF.[26] Using the ADHERE registry, Fonarow et al. was able to risk stratify patients into low, intermediate and high risk representing a 2–22% range for in hospital mortality using levels of urea, creatinine and SBP with an area under the curve of 0.67–0.69. [27]

As there is a clear trade-off between the simplicity and ease of use of available prediction tools and the accuracy of prediction, the challenge is to choose an optimal tool for the task. Three of the easily obtainable routine admission tests (albumin, sodium and urea) can constitute a simple prognostic score with one point assigned for each abnormal result. This score was able to risk stratify 30-day mortality with a range of 1%–21% and one-year mortality in a range of 12–56%. Compared with the full model and other similar survival prediction tools this short score, based on the standard cut-off point for the normal range of the routine laboratory tests, allows for rapid implementation on the level of the treating physician. Its simplicity eliminates the need for elaborate calculations requiring bed-side computers or memorization of the different schemes for the score point assignment.

Our study does not necessarily present new information on the potential mortality predictors in patients with acute decompensated heart failure. Rather we have shown that the use of simple and relatively inexpensive laboratory tests may achieve the same degree of accuracy in predicting the outcomes as more contemporary and sophisticated biomarkers. One can assume that the biomarkers are not independent from the patient’s clinical condition. The severity of the disease can be evident by analyzing
Figure 5. Calibration plot for 30-days and 1-year mortality. Model included laboratory tests, demographics and comorbidities. doi:10.1371/journal.pone.0012184.g005
number of the patient’s clinical signs and symptoms as well as laboratory tests. The added value of the individual test is usually small (though sometimes important); therefore the approach based on the entire clinical picture might provide a greater insight into the individual patient prognosis. Moreover, the likelihood of survival can be determined reliably only in populations and not in individuals.[28]

Our study has a number of limitations. We did not have a direct comparison to discriminative abilities of more novel biomarkers such as BNP/NT-proBNP. BNP/NT-proBNP have been shown to be predictive of mortality in several studies of HF, however these tests are not routinely available in many countries and add significantly to laboratory costs.[27,29] The study was only performed in one country; however the care of patients with HF in Israel has been shown to be similar to that of European and North American countries.[30] Patients included in this retrospective study were those with a discharge diagnosis of HF as recorded by the treating physicians and coded with ICD-9 classification without consistent capturing of patients’ functional status (NYHA class). We were not able to separate between the first incidence of HF admission in life and repeated admission. It might be expected that repeated admission patients have different prognosis. Our analysis included data from the hospitals operating under the centrally managed universal health system (Clalit Health Services), therefore it might be expected that the models will perform differently in other countries. Lastly, although the participating hospitals belong to the same health care system, some variations in laboratory measurements might exist.

The strength of our study is the large number of consecutive, non-selected patients studied and the applicability of the score to all patients presenting to the hospital with a diagnosis of HF. In addition we had the complete follow-up data on long term mortality. Our analysis shows that based on the administrative data analysis (patient demographics, recorded diagnosis and number of laboratory tests results) the reasonable degree of the prognostication can be achieved.

In summary, we have confirmed that a number of demographic characteristics, comorbidities and abnormal laboratory tests are predictive of 30-day and one-year mortality in patients admitted

### Table 5. Mortality rates stratified by the score.

| Score | 0 points | 1 point | 2 points | 3 points |
|-------|----------|---------|----------|----------|
| 30-day mortality rate | derivation cohort | 1.0% | 5.1% | 13.0% | 17.8% |
| validation cohort | 1.7% | 6.7% | 13.5% | 23.4% |
| 1-year mortality rate | derivation cohort | 11.2% | 23.6% | 39.9% | 55.3% |
| validation cohort | 12.0% | 25.0% | 40.0% | 55.9% |

For each abnormal result in admission laboratory test (urea $\geq 43$ mg/dL, sodium $<136$ meq/L and albumin $<3.5$ g/dL) one point was assigned. Patient population was stratified by the total combined score. Mortality rates presented for derivation cohort (3 hospitals, 3,941 subjects) and validation cohort (4 hospitals, 4,305 subjects).

doi:10.1371/journal.pone.0012184.t005

Figure 6. Kaplan-Meier curves for one-year mortality according to risk points. For each abnormal result in admission laboratory test (urea $\geq 43$ mg/dL, sodium $<136$ meq/L and albumin $<3.5$ g/dL) one point was assigned. Patient population was stratified by the total combined score. Log-rank test, $p<0.001$.

doi:10.1371/journal.pone.0012184.g006
with decompensated HF. A small panel of easily obtainable laboratory tests can help risk-stratify patients with HF. These results need to be prospectively confirmed in other cohorts of HF patients.

**References**

1. Rosamond W, Flegel K, Friday G, Furie K, Go A, et al. (2007) Heart Disease and Stroke Statistics-2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69–171.
2. Mitchell JE (2007) Emerging role of anemia in heart failure. Am J Cardiol 99: 15D–20D.
3. Cooper HA, Exner DV, Waclawiw MA, Domanski MJ (1999) White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 84: 252–257.
4. De Domenico S, White M, Tardif JC, Bourassa MG, Racine N, et al. (2006) Temporal increases in subclinical levels of inflammation are associated with adverse clinical outcomes in patients with left ventricular dysfunction. J Card Fail 12: 353–359.
5. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, et al. (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47: 1987–1996.
6. Smith GL, Shlipak MG, Havranek EP, Foody JM, Massoudi FA, et al. (2006) Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med 166: 1134–1142.
7. Adrogue HJ, Madidas NE (2000) Hyponatremia. N Engl J Med 342: 1581–1589.
8. Oren RM (2005) Hyponatremia in congestive heart failure. Am J Cardiol 95: 2B–7B.
9. Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, et al. (2005) Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Methylene for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111: 2454–2460.
10. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, et al. (2004) Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. JAMA 292: 552–553.
11. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, et al. (2003) Uric acid and chronic cardiac failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107: 1991–1997.
12. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B, Antonilos MJ, Ruiperez JA, et al. (2007) Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 9: 518–524.
13. Anker SD, Sharma R (2002) The syndrome of cardiac cachexia. Int J Cardiol 83: 51–66.
14. Horwich TB, Kalandar-Zadeh K, MaxLellan RW, Fonarow GC (2008) Albumin levels predict survival in patients with systolic heart failure. Am Heart J 155: 883–889.
15. Sewdarsen M, Vythilingum S, Jalal I, Becker JF (1989) Prognostic importance of admission plasma glucose in diabetic and non-diabetic patients with acute myocardial infarction. Q J Med 71: 461–466.
16. Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW, et al. (2004) Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 164: 982–983.
17. Battaglia M, Pesner D, Juni P, Egger M, Bucher HC, et al. (2006) Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: systematic review of test accuracy studies. Arch Intern Med 166: 1073–1080.
18. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, et al. (2007) Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13: 42–49.
19. Maisel A. Biomarkers in the Assessment of Congestive Heart Failure: Mid-Regional pro-Adrenomedullin (MR-proADM) vs BNP &NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial; 2008; New-Orleans, LA.
20. Charbonneau J, Mihalcescu CR, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.
21. Wang TJ, Gona P, Larson MG, Toller GH, Levy D, et al. (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355: 2631–2639.
22. Haste T, Tibshirani RJ (1990) Generalized Additive Models. New York: Chapman and Hall.
23. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837–845.
24. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, et al. (2003) Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290: 2581–2587.
25. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goon JE, et al. (1997) Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95: 2660–2667.
26. Levy WC, Mozaffarian D, Linker DT, Suturetha SC, Anker SD, et al. (2006) The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113: 1424–1433.
27. Fonarow GC, Adams KF, Jr., Abraham WT, Yancy CW, Boscardin WJ (2005) Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293: 572–580.
28. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: 1977–2016.
29. Metra M, Nodari S, Parinello G, Specchia G, Bontempra L, et al. (2007) The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin T. Eur J Heart Fail.
30. Jotkowitz AB, Porath A, Shotan A, Mittelman M, Grossman E, et al. (2006) Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey. Isr Med Assoc J 8: 873–879.

**Author Contributions**

Conceived and designed the experiments: VN MP DZ LF RN AJ AP. Performed the experiments: VN MP DZ LF RN AJ AP. Analyzed the data: VN MP DZ LF RN AJ AP. Contributed reagents/materials/analysis tools: VN MP DZ LF RN AJ AP. Wrote the paper: VN MP DZ LF RN AJ AP. All authors had access to the data and a role in writing the manuscript.